100 related articles for article (PubMed ID: 23062910)
21. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
22. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
23. Safety of neurokinin-1 receptor antagonists.
Muñoz M; Coveñas R
Expert Opin Drug Saf; 2013 Sep; 12(5):673-85. PubMed ID: 23706125
[TBL] [Abstract][Full Text] [Related]
24. Effects of neuroimmune axis modulation by aprepitant on antipruritic and global disease severity in patients with cutaneous T-cell lymphoma.
Kwatra SG; Boozalis E; Kwatra MM
Br J Dermatol; 2018 May; 178(5):1221-1222. PubMed ID: 29352478
[No Abstract] [Full Text] [Related]
25. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Hafizi S; Chandra P; Cowen J
Br J Psychiatry; 2007 Oct; 191():282-4. PubMed ID: 17906236
[TBL] [Abstract][Full Text] [Related]
26. More on aprepitant for erlotinib-induced pruritus.
Gerber PA; Buhren BA; Homey B
N Engl J Med; 2011 Feb; 364(5):486-7. PubMed ID: 21288112
[No Abstract] [Full Text] [Related]
27. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
28. Aprepitant for the management of refractory emesis in a patient with a small bowel carcinoid tumor.
Kyeremateng S; Boland JW
J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):135-7. PubMed ID: 24833205
[TBL] [Abstract][Full Text] [Related]
29. What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.
Biazus Soares G; Guitart J; Yosipovitch G
Am J Clin Dermatol; 2024 Jan; 25(1):67-77. PubMed ID: 37971624
[TBL] [Abstract][Full Text] [Related]
30. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
[TBL] [Abstract][Full Text] [Related]
31. The use of aprepitant in brachioradial pruritus.
Ally MS; Gamba CS; Peng DH; Tang JY
JAMA Dermatol; 2013 May; 149(5):627-8. PubMed ID: 23677105
[No Abstract] [Full Text] [Related]
32. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
33. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
34. Tranexamic acid induces kaolin intake stimulating a pathway involving tachykinin neurokinin 1 receptors in rats.
Kakiuchi H; Kawarai-Shimamura A; Kuwagata M; Orito K
Eur J Pharmacol; 2014 Jan; 723():1-6. PubMed ID: 24333477
[TBL] [Abstract][Full Text] [Related]
35. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
36. Influence of a neurokinin-1 receptor antagonist (aprepitant) on gastric sensorimotor function in healthy volunteers.
Ang D; Pauwels A; Akyuz F; Vos R; Tack J
Neurogastroenterol Motil; 2013 Dec; 25(12):e830-8. PubMed ID: 23991829
[TBL] [Abstract][Full Text] [Related]
37. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract][Full Text] [Related]
38. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma.
Borja-Consigliere HA; López-Pestaña A; Vidal-Manceñido MJ; Tuneu-Valls A
Actas Dermosifiliogr; 2014 Sep; 105(7):716-8. PubMed ID: 24139470
[No Abstract] [Full Text] [Related]
39. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.
Santini D; Vincenzi B; Guida FM; Imperatori M; Schiavon G; Venditti O; Frezza AM; Berti P; Tonini G
Lancet Oncol; 2012 Oct; 13(10):1020-4. PubMed ID: 22995650
[TBL] [Abstract][Full Text] [Related]
40. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
